Eyal Gura
Angel Investor
Hod Hasharon, Israel
Eyal Gura is a Series A investor in Hod Hasharon focused on Software and Health Care. Eyal Gura is based out of Hod Hasharon, HaMerkaz and is the co-founder of MAPS Israel. Eyal previously worked at Zebra Medical Vision as a co-founder, president, and chairman of the board. Eyal Gura attended the Reichman University.
- Total investments:
- 26
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Eyal Gura invests in
Stages Eyal Gura invests in
Countries Eyal Gura invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1M–$3.6M
- Series A
- $7.1M–$40M
- Series B
- $14M–$21M
Investment Focus
Industry
- Software 6 (23%)
- Health Care 5 (19%)
- Artificial Intelligence 5 (19%)
- Mobile 4 (15%)
- Internet 3 (12%)
Stage
- Series A 8 (31%)
- Seed 7 (27%)
- Series B 3 (12%)
- Angel 2 (8%)
- Series C 2 (8%)
Country
- United States 11 (42%)
- Israel 8 (31%)
- Belgium 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for medical purpose. | $3.6M / Seed / May 03, 2026 | ||
| Taranis is a leading precision agriculture intelligence platform that uses sophisticated computer vision, data science, and deep learning algorithms to effectively monitor fields. The system enables farmers to make informed decisions by detecting early symptoms of weeds, uneven emergence, nutrient deficiencies, disease or insect infestations, waterdamage, and machinery problems. Overseeing millions of acres of farmland in Argentina, Brazil, Russia, Ukraine, and the United States, Taranis gives farmers the tools to address issues in real-time, increasing yields and cutting costs. Taranis employs over 100 people worldwide and is headquartered in San Francisco with subsidiaries in Israel, Argentina, and Brazil. | $40M / Series D / Sep 07, 2022 | ||
| Imagene AI provides AI-based molecular testing for cancer, leveraging the patient's histological data for personalized therapy.Our mission at Imagene is to assist cancer patients in receiving the optimal treatment medicine can offer by leveraging AI to detect, in real-time, a broad range of cancerous biomarkers and genomic insights from thebiopsy image alone. By doing so, Imagene overcomes economical, logistical, and technological barriers to reach the full potential of precision medicine for cancer patients.Through collaborations with top-tier medical centers and pharmaceutical companies, Imagene is revolutionizing molecular screening for both clinical practice and research.Our success derives from our cutting-edge technology and talented multidisciplinary team of data scientists, biologists, software engineers, and medical experts. | $18.5M / Series A / May 02, 2022 | ||
| Theator is a surgical intelligence platform that combines artificial intelligence and computer vision to improve surgeon performance. Introducing Surgical Intelligence, the platform powered by Visual AI that puts defining intraoperative moments in the hands of surgeons so they can continuously perfect their craft. As experts in both surgery andcomputer-vision technology, Theator is partnering with visionary surgeons and hospitals to help create a more transparent OR, while empowering surgeons to raise their expertise to the highest possible level. Pioneering the Surgical Intelligence revolution, Theator is paving the path for real-time surgery decision-support in the future, while helping to create a stronger healthier world today. | $15.5M / Series A / Feb 09, 2021 | ||
| TechSee is a technology and technical support company that specializes in visual technology and augmented reality. The company’s technology combines AI with deep machine learning, proprietary algorithms, and big data to deliver a scalable cognitive system that becomes smarter with every customer support interaction.It offers a smart visualinteractive platform that enables its users to interact with their customer through a live virtual channel and guide them using augmented reality and annotations. TechSee was founded by Eitan Cohen, Amir Yoffe, and Gabby Sarussi in 2015 and is headquartered in Tel Aviv, Israel. | $30M / Series C / Oct 26, 2020 | ||
| DataLoop's data management and annotation platform streamline the process of preparing visual data for machine and deep learning. Dataloop is used for building and deploying powerful computer vision pipelines – data labeling, automating data ops, customizing production pipelines, and weaving the human-in-the-loop for data validation. Thiseliminates data challenges for companies, allowing them to focus their resources on their core business. The company was founded in 2017 and is based in Herzliya, Tel Aviv. | $11M / Series A / Oct 14, 2020 | ||
| Awell Health enables healthcare organizations to create, implement, and continually update care pathways to improve patient outcomes. While public opinion and many new players in the digital health space believe data is the answer to solving the healthcare crisis, Awell Health believes the focus needs to be on reorganizing largely paper-based anddisjointed processes. | $2.4M / Seed / Sep 23, 2020 | ||
| Theator is a surgical intelligence platform that combines artificial intelligence and computer vision to improve surgeon performance. Introducing Surgical Intelligence, the platform powered by Visual AI that puts defining intraoperative moments in the hands of surgeons so they can continuously perfect their craft. As experts in both surgery andcomputer-vision technology, Theator is partnering with visionary surgeons and hospitals to help create a more transparent OR, while empowering surgeons to raise their expertise to the highest possible level. Pioneering the Surgical Intelligence revolution, Theator is paving the path for real-time surgery decision-support in the future, while helping to create a stronger healthier world today. | Seed / Aug 05, 2019 | ||
| Venn creates a new way of urban neighboring by managing homes, creating shared spaces, supporting hyperlocal business initiatives and services, programs events, and facilitating community engagement – all on a neighborhood-wide level. Operating by the motto, “If they build it, they will stay,” venn’s platform encourages urbanites to become activecreators and participants in the development of their community and enables developing neighborhoods to become as vibrant and desirable as the downtown core. Founded in 2016 by people raised in the Big City and in cooperative communities, venn is a new movement of neighboring that impacts tens of thousands of people in three cities (Tel Aviv, Brooklyn, and Berlin) with +75 employees | $40M / Series A / Jun 25, 2019 | ||
| Wi-Charge is the award-winning developer and provider of safe and reliable wireless power solutions for distances of 10m/30ft and beyond. Our revolutionary technology reshapes the consumer, commercial and industrial environments by seamlessly continuous powering devices without charging cables or batteries. Wi-Charge is set out to address the#1 growing pain of the digital era - the need to frequently recharge or replace batteries. The benefits of our solutions include: * Cost savings- eliminating wire cords and batteries. * Hassle free charging. * Earth friendly sustainable/green energy. - Increasing ESG rating. Our technology is currently utilized by the smart retail and smart building environments, wirelessly powering products such as advertising displays and smart door locks. To be followed by wirelessly charging products in the consumer & commercial mass markets of laptops, tablets, cellphone devices, gaming controllers, handheld scanners, light EVs and more. Founded in 2010 our deep-tech solutions are based on scientific breakthroughs in the fields of photonics and semiconductors doing to power what Wi-Fi did to communications. | $14M / Series B / May 27, 2019 | ||
| See all 26 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Eyal Gura invest in?
Eyal Gura invests primarily in Software, Health Care and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 26 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Eyal Gura invest in?
Eyal Gura typically joins rounds of $1M–$3.6M at Seed, $7.1M–$40M at Series A and $14M–$21M at Series B. These are whole funding-round sizes, not Eyal Gura's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Eyal Gura took part in.
How do I contact Eyal Gura?
Public channels for Eyal Gura include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Eyal Gura last invest?
The most recent investment recorded for Eyal Gura closed in May 2026. Shizune tracks 26 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
